Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward.

Mechanical thrombectomy beats anticoagulation alone in STORM-PE
Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.
Shockwave Medical’s IVL catheter for peripheral lesions linked to positive 1-year data
The new findings, presented during a late-breaking presentation, focused on 110 PAD patients treated with Shockwave Medical's Javelin Peripheral IVL Catheter.
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.
Drug-coated balloons an effective tool in the battle against femoropopliteal disease
Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes.

New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD

Medtronic data presented today reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.

The Eluvia drug-eluting stent continues to demonstrate positive outcomes in long lesion IMPERIAL sub-study

Boston Scientific announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.

Medtronic Unveils New Aortic and Peripheral Data from Two Late-Breaking Clinical Trials at VIVA 2015

Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.

Vascular Interventional Advances (VIVA)

Mechanical thrombectomy beats anticoagulation alone in STORM-PE

Shockwave Medical’s IVL catheter for peripheral lesions linked to positive 1-year data

Bioresorbable BTK stent superior to ballon angioplasty at 2 years

Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients

Drug-coated balloons an effective tool in the battle against femoropopliteal disease